Prospects in Pharmaceutical Sciences最新文献_第4页

The Glucagon-Like Peptide-1 Analogues therapy in the non-diabetic patients 胰高血糖素样肽-1类似物在非糖尿病患者中的治疗

Prospects in Pharmaceutical Sciences Pub Date : 2023-03-13 DOI: 10.56782/pps.127

Agnieszka Sienicka, Krzysztof Kubasik, Agata Pisula

{"title":"The Glucagon-Like Peptide-1 Analogues therapy in the non-diabetic patients","authors":"Agnieszka Sienicka, Krzysztof Kubasik, Agata Pisula","doi":"10.56782/pps.127","DOIUrl":"https://doi.org/10.56782/pps.127","url":null,"abstract":"Glucagon like peptide-1 (GLP-1) receptor agonists are a group of hypoglycemic drugs that are used primarily to treat type 2 diabetes both as monotherapy and in combination with other antidiabetic drugs. In contrast to most hypoglycemic drugs, GLP-1 receptor agonists not only do not cause weight gain, but can even lead to weight reduction. This is why they are recently also increasingly used in the treatment of obesity in patients without type 2 diabetes. Current research indicate that liraglutide and semaglutide are effective and safe methods of treatment for overweight and obesity in patients without diabetes. GLP-1 receptor agonists’ mechanism of action is related to the incretin system. They lowers glucose concentrations by increasing insulin secretion and suppressing glucagon release. Moreover, they cause a retardation of gastric emptying and affect the central nervous system, resulting in a decrease in appetite and stimulation of satiety. In addition, a rising number of research studies show that GLP-1 receptor agonists may also have beneficial effects in the treatment of other conditions, such as nervous and cardiovascular diseases, metabolic diseases or endocrine disorders. Due to the new findings, even more research should be carried out to further investigate and describe the multidirectional effects of these drugs.","PeriodicalId":295830,"journal":{"name":"Prospects in Pharmaceutical Sciences","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126921510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The method of direct determination of manganese in fresh parsley leaves and roots using capillary electrophoresis method. 采用毛细管电泳法直接测定新鲜欧芹叶和根中锰的含量。

Prospects in Pharmaceutical Sciences Pub Date : 2023-02-21 DOI: 10.56782/pps.125

Błażej Grodner, M. Jelińska

引用次数: 0

Does testosterone intake affect diagnosing primary HIV infection? 睾酮摄入是否影响诊断原发性HIV感染?

Prospects in Pharmaceutical Sciences Pub Date : 2023-01-26 DOI: 10.56782/pps.124

Olga Grelewicz, Gabriela Kulbacka, T. Mikuła, A. Wiercińska-Drapało

引用次数: 1

Analysis of the activity of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in the field of clinical trials, registration of medicinal products and monitoring of adverse drug reactions in 2017-2021 2017-2021年波兰药品、医疗器械和杀菌剂产品注册办公室在临床试验、药品注册和药物不良反应监测领域的活动分析

Prospects in Pharmaceutical Sciences Pub Date : 2022-12-30 DOI: 10.56782/pps.120

Ł. Dobrek

{"title":"Analysis of the activity of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in the field of clinical trials, registration of medicinal products and monitoring of adverse drug reactions in 2017-2021","authors":"Ł. Dobrek","doi":"10.56782/pps.120","DOIUrl":"https://doi.org/10.56782/pps.120","url":null,"abstract":"The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (ORMP) is the state registration authority that grants the marketing authorization for medicinal products on the pharmaceutical market in Poland. ORMP is also involved in approving and controlling clinical trials and in safety of pharmacotherapy (pharmacovigilance) by collecting and analysing reports of adverse drug reactions (ADR). The aim of the study was to review the activity of ORMP in the field of 3 basic competences of this authority: clinical trials, registration of medicinal products and pharmacovigilance in the last 5 years. The evaluation was carried out by the method of document analysis on the basis of data contained in annual bulletins of medicinal products for the years 2017-2021 published by ORMP. In 2017-2021, an increasing trend of clinical trials submitted to ORMP was observed, and they were mainly in phase II and III. Most of the medicinal products introduced to the Polish pharmaceutical market in 2017-2021 were drugs prescribed by a doctor, registered in a decentralized procedure, used in diseases of the nervous and cardiovascular systems and in the treatment of cancer. A relatively low activity of ORMP in monitoring the safety of pharmacotherapy was demonstrated, which was a consequence of low activity of medical staff in the spontaneous ADR reporting. The conducted analysis confirmed the key role of ORMP in surveillance of clinical trials and introducing new medicinal products to the pharmaceutical market in Poland but also indicated the need for increased activity in the area of pharmacovigilance.","PeriodicalId":295830,"journal":{"name":"Prospects in Pharmaceutical Sciences","volume":"106 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128131931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Zarys historii syntezy leków ze szczególnym uwzględnieniem leków przeciwnowotworowych i przeciwbakteryjnych

Prospects in Pharmaceutical Sciences Pub Date : 2022-11-08 DOI: 10.56782/pps.121

J. Warguła

引用次数: 0

Isolation of trachelogenin 4-O-β-D-glucoside from the fruits of Carthamus tinctorius L. 红花果实中4-O-β- d -葡萄糖苷的分离。

Prospects in Pharmaceutical Sciences Pub Date : 2022-08-18 DOI: 10.56782/pps.39

Andrzej Patyra, Marcin Kołakowski, M. Dudek, A. Kiss

引用次数: 0

Anti-leukotriene drugs in the therapy of inflammatory diseases 抗白三烯类药物在炎性疾病治疗中的应用

Prospects in Pharmaceutical Sciences Pub Date : 2022-08-17 DOI: 10.56782/pps.38

Bartłomiej Pyrak, Karolina Rogacka, D. M. Pisklak

{"title":"Anti-leukotriene drugs in the therapy of inflammatory diseases","authors":"Bartłomiej Pyrak, Karolina Rogacka, D. M. Pisklak","doi":"10.56782/pps.38","DOIUrl":"https://doi.org/10.56782/pps.38","url":null,"abstract":"\u0000A key part of many chronic diseases is inflammation controlled by inflammatory mediators. Regulation of their function allows to mute the inflammatory response, which is a desired effect in the treatment of inflammatory diseases. The source of mediators is arachidonic acid, converted to pro-inflammatory mediators by cyclooxygenases (COX) or lipooxygenases (LOX). The 5-LOX pathway is full of target points for regulation of biosynthesis of cysteinyl leukotrienes (CysLT) – one of the major classes of inflammatory mediators. These compounds exert their activity through specific leukotriene receptors – first (CysLT1R) and second (CysLT2R). Drugs that inhibit CysLT synthesis as well as leukotriene receptors antagonists (LTRA) form group of drugs known as anti-leukotriene drugs. Currently, only a few representatives of this group are available in the pharmacies around the world: the 5-LOX inhibitor – zileuton – and three CysLT1R antagonists – montelukast, pranlukast, zafirlukast. LTRAs due to their wide range of anti-inflammatory effects, are a group of drugs with a high potential in the treatment of inflammatory diseases. The study of new applications of known LTRAs and the search for new members of the LTRA group are the main directions of development in this field of pharmacy. This work summarizes the benefits of using anti-leukotriene drugs in the treatment od chronic diseases and presents new directions of using LTRAs. \u0000","PeriodicalId":295830,"journal":{"name":"Prospects in Pharmaceutical Sciences","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114465294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-vitamin K antagonist oral anticoagulants (NOAC) in nonvalvular atrial fibrillation – in-group comparison 非维生素K拮抗剂口服抗凝剂(NOAC)治疗非瓣膜性房颤的组内比较

Prospects in Pharmaceutical Sciences Pub Date : 2022-07-20 DOI: 10.56782/pps.36

A. Piasecki

{"title":"Non-vitamin K antagonist oral anticoagulants (NOAC) in nonvalvular atrial fibrillation – in-group comparison","authors":"A. Piasecki","doi":"10.56782/pps.36","DOIUrl":"https://doi.org/10.56782/pps.36","url":null,"abstract":"\u0000Atrial fibrillation (AF) is a major and widespread health problem. Its main and most threatening complication, ischemic stroke, is responsible for a great number of deaths and disability worldwide. This makes anticoagulation a priority in AF management. Non-vitamin K antagonist oral anticoagulants (NOAC) are currently the most effective and safe option for patients with nonvalvular atrial fibrillation. Rivaroxaban, apixaban, edoxaban and dabigatran are non-inferior to warfarin in terms of stroke and systemic embolism prevention. However, warfarin use is associated with higher rates of major bleedings than any NOAC. Different drugs and mechanism of action among NOACs may result in differences in terms of efficacy and safety between them. This review aims to assess these differences by summarizing data available in online databases and European Society of Cardiology guidelines. There are major studies comparing each of NOACs to warfarin, however there is only limited data comparing apixaban, rivaroxaban and dabigatran directly. Both direct and indirect comparisons suggest that apixaban, rivaroxaban and dabigatran use is associated with similar reduction of stroke and systemic embolism risk. In terms of safety, anticoagulation with apixaban results in lower major bleeding risk relative to dabigatran and rivaroxaban. \u0000","PeriodicalId":295830,"journal":{"name":"Prospects in Pharmaceutical Sciences","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128599487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Flozins in heart failure – a new reimbursement indication 氟罗津治疗心力衰竭——一个新的报销指征

Prospects in Pharmaceutical Sciences Pub Date : 2022-06-14 DOI: 10.56782/pps.35

Jakub Olszewski, Katarzyn Kozon, Andrzej Patyra

{"title":"Flozins in heart failure – a new reimbursement indication","authors":"Jakub Olszewski, Katarzyn Kozon, Andrzej Patyra","doi":"10.56782/pps.35","DOIUrl":"https://doi.org/10.56782/pps.35","url":null,"abstract":"\u0000 \u0000 \u0000Sodium-glucose cotransporter-2 inhibitors, called flozins, are a relatively new group of drugs that quickly have gained recognition among diabetologists, cardiologists, and nephrologists. The mechanism of their action is based on inhibition of the reabsorption of glucose inside the proximal tubule of nephron, which results in lowering a blood glucose level. In addition, flozins reduce blood pressure, cause weight loss, and reduce the risk of death from cardiovascular causes. Until recently, the potential of flozins was used only to treat patients with type 2 diabetes. The clinical trials published several years ago on three representatives of this group of drugs: dapagliflozin, empagliflozin, and canagliflozin, showed that their use in patients with type 2 diabetes and cardiovascular disease reduces the risk of hospitalization and death from cardiovascular causes. These trials prompted scientists to extend research on the effectiveness of flozins in lowering the risk of complications of heart failure and cardiovascular diseases. Subsequent studies showed that regardless of whether a patient with cardiovascular disease has diabetes, the effectiveness of empagliflozin and dapagliflozin is comparable in reducing hospitalizations and cardiovascular deaths. These discoveries resulted in flozins appearing in the European Society of Cardiology guidelines as one of the first-line drugs in heart failure with reduced ejection fraction. In Poland, empagliflozin, and dapagliflozin obtained a new reimbursement indication on May 1, 2022 – chronic heart failure with reduced ejection fraction in patients meeting specific criteria. It’s a significant step in treating heart failure, which is still a substantial cause of death and hospitalizations in Poland, especially among the aging population. The aim of this review is to show the path that flozins have gone from being an antidiabetic drug to being the first-line drug in the treatment of heart failure and to draw the attention of readers to the new reimbursement indication of flozins in Poland. \u0000 \u0000 \u0000","PeriodicalId":295830,"journal":{"name":"Prospects in Pharmaceutical Sciences","volume":"50 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124952102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

CZY NADWAGA LUB NIEDOWAGA MŁODYCH ZDROWYCH KOBIET W OKRESIE PREKONCEPCYJNYM MOŻE PROGNOZOWAĆ ZABURZONĄ HOMEOSTAZĘ HORMONÓW TARCZYCY ORAZ SKŁADU BIAŁEK W SUROWICY

Prospects in Pharmaceutical Sciences Pub Date : 2022-06-09 DOI: 10.56782/pps.4

A. Strawa, E. Skarżyńska, Barbara Lisowska-Myjak

引用次数: 0